Company Profile

PFIZER LTD.

NSE : PFIZERBSE : 500680ISIN CODE : INE182A01018Industry : Pharmaceuticals & DrugsHouse : Pfizer - MNC
BSE5104.10-16.15 (-0.32 % )
PREV CLOSE (Rs.) 5120.25
OPEN PRICE (Rs.) 5100.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 4633
TODAY'S LOW / HIGH (Rs.)5080.50 5120.80
52 WK LOW / HIGH (Rs.)3588.15 5875
NSE5104.50 -15.4 (-0.3 % )
PREV CLOSE(Rs.) 5119.90
OPEN PRICE (Rs.) 5099.95
BID PRICE (QTY) 5104.50 (2 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 44344
TODAY'S LOW / HIGH(Rs.) 5060.00 5124.85
52 WK LOW / HIGH (Rs.)3461 5900

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 6.47
TTM EPS (Rs.) 108.83
P/E Ratio 46.90
Book Value (Rs.) 468.23
Face Value (Rs.) 10
MCap (Rs. in Mn) 233501.00
Price/Earning (TTM) 38.54
Price/Sales (TTM) 10.86
Price/Book (MRQ) 10.90
PAT Margin (%) 23.66
ROCE (%) 20.38
Incorporation Year : 1950

Management Info :

R A Shah - Chairman S Sridhar - Managing Director

Registered Office :

Address : The Capital, 1802/1901,Plot No.c-70, G Block,Bandra Kurla Complex, Bandra (East),
Mumbai,
Maharashtra-400051

Phone : 91 22 6693 2000

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
13Oct10-13-2020$Pfizer modifies protocol for virus vaccine study Pfizer modifies protocol for

Pfizer has modified the protocol for its late-stage study of its vaccine against the new coronavirus, this time to include more young participants. The company has received permission from the Food and Drug Administration to include adolescents aged 12 through 15 in its global COVID-19 vaccine study.

The company originally planned for 30,000 participants, but in September expanded that to 44,000 people. That increase was made to boost diversity in the trial population, specifically by including 16- and 17-year-old teens, as well as stable patients with some common chronic infections: hepatitis B, hepatitis C and HIV.

Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.

Pfizer has modified the protocol for its late-stage study of it..
28Jul07-28-2020$Pfizer reports 10% rise in Q1 net profit Pfizer reports 10% rise in Q

Pfizer has reported results for first quarter ended June 30, 2020.

The company has reported 10.32% rise in its net profit of Rs 124.45 crore for the quarter under review as against Rs 112.81 crore for the same quarter in the previous year. However, total income of the company decreased 8.30% at Rs 532.09 crore for Q1FY21 as compared Rs 580.23 crore for the corresponding quarter previous year.

Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.

Pfizer has reported results for first quarter ended June 30, 20..
18Mar03-18-2020$Pfizer informs about loss of share certificate Pfizer informs about loss of

Pfizer has informed about loss of share certificate/ issue of duplicate share certificate, pursuant to Regulation 39(3) of SEBI (Listing obligations and disclosure requirement) Regulations 2015..

The above information is a part of company’s filings submitted to BSE.




Pfizer has informed about loss of share certificate/ issue of d..
03Mar03-03-2020$Pfizer’s parent company identifies some antiviral compounds to inhibit coronavirus: Report Pfizer’s parent company id

Pfizer’s parent company in the US has reportedly found some antiviral compounds that have the potential to inhibit coronavirus. The company is engaging with a third party to screen the compounds and it hopes that they would get the results from screening by the end of March. If any of the compounds are successful the company would start testing them by the end of the year.

Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.

Pfizer’s parent company in the US has reportedly found some a..
03Mar03-03-2020$Pfizer soars on the buzz of its parent company identifies some antiviral compounds to inhibit coronavirus Pfizer soars on the buzz of

Pfizer is currently trading at Rs. 4416.75, up by 157.90 points or 3.71% from its previous closing of Rs. 4258.85 on the BSE.

The scrip opened at Rs. 4274.95 and has touched a high and low of Rs. 4929.85 and Rs. 4271.15 respectively. So far 36100 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 4,929.85 on 03-Mar-2020 and a 52 week low of Rs. 2797.50 on 23-Aug-2019.

Last one week high and low of the scrip stood at Rs. 4929.85 and Rs. 4054.85 respectively. The current market cap of the company is Rs. 20213.41 crore.

The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 16.72% and 19.36% respectively.

Pfizer’s parent company in the US has reportedly found some antiviral compounds that have the potential to inhibit coronavirus. The company is engaging with a third party to screen the compounds and it hopes that they would get the results from screening by the end of March. If any of the compounds are successful the company would start testing them by the end of the year.

Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.

Pfizer is currently trading at Rs. 4416.75, up by 157.90 points..
Financials More
Rs. in Millions
QTR Sep 20 ANNUAL 20
Net Profit1313.75091.3
Gross Profit 1830.3 6424.9
Operating Profit 2154.77565.8
Net Sales 5954.121516.5
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Procter&Gamble Healt (BSE)
 6878.70 (8.26%)
M.Cap ( in Cr)
11418.22
Divis Lab (BSE)
 3607.60 (1.76%)
M.Cap ( in Cr)
95770.44
Ipca Laboratories (BSE)
 2196.85 (2.86%)
M.Cap ( in Cr)
27867.51
JB Chem & Pharma (BSE)
 994.25 (4.41%)
M.Cap ( in Cr)
7683.77
IOL Chem & Pharma (BSE)
 780.65 (5.02%)
M.Cap ( in Cr)
4582.85
Shareholding Pattern More
PROMOTERS 63.92 %
FI/BANKS/INSURANCE 2.56 %
NON-INSTITUTION 19.18 %
MUTUAL FUNDS/UTI 10.48 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes